Navitoclax

Navitoclax Uses, Dosage, Side Effects, Food Interaction and all others data.

Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others.

Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying.

Trade Name Navitoclax
Generic Navitoclax
Navitoclax Other Names Navitoclax
Type
Formula C47H55ClF3N5O6S3
Weight Average: 974.613
Monoisotopic: 973.295508909
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Navitoclax
Navitoclax

How Navitoclax works

Navitoclax targets the Bcl-2 family of proteins, the major negative regulators of apoptosis. The Bcl-2 proteins, including Bcl-2, Bcl-xL, and Bcl-w, work by binding to two other groups of proteins-the executioners (Bax, Bak) that actually start the destruction pathway, and the sentinel proteins. Cancer cells frequently overexpress the Bcl-2-like proteins, and thus, when they sustain DNA damage-from radiation, for example-they continue growing. Preventing the Bcl-2-like proteins from binding to the executioners might be able to trigger cell death in the tumor.

Innovators Monograph

You find simplified version here Navitoclax

*** Taking medicines without doctor's advice can cause long-term problems.
Share